{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:25:52Z","timestamp":1787318752686,"version":"build-2736575974"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023QH334"],"award-info":[{"award-number":["ZR2023QH334"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The advent of immune checkpoint inhibitors (ICIs) has revolutionized cancer treatment but is associated with immune-related adverse events (irAEs) that can involve multiple organ systems.Steroid-refractory immune checkpoint inhibitor associated myocarditis, defined as persistent or progressive myocardial injury despite high-dose corticosteroids requiring escalation of immunosuppression, represents a life-threatening clinical challenge with limited therapeutic options. This case report describes a 75-year-old female patient with deficient mismatch repair sigmoid colon adenocarcinoma who developed severe multi-organ irAEs, including myositis, hepatitis, and steroid-refractory myocarditis 25 days after receiving QL1706 (a PD-1\/CTLA-4 bispecific antibody). Initial intervention with high-dose glucocorticoid pulse therapy combined with intravenous immunoglobulin failed to control the myocardial injury. The clinical course was further complicated by endocrine involvement and hematological toxicity following second-line immunosuppression with mycophenolate mofetil. After tofacitinib administration, the patient\u2019s clinical symptoms and laboratory findings showed significant improvement. Notable adverse effects included oral mucositis, diarrhea, and a pulmonary fungal infection, which were managed supportively. This case highlights the potential role of tofacitinib in managing complex, steroid-refractory multi-organ irAEs. However, the significant infection risk underlines the necessity for vigilant monitoring and prophylactic strategies. Further prospective studies are needed to define the efficacy and safety of JAK inhibitors in this setting.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1778284","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:34:35Z","timestamp":1774935275000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Successful treatment of steroid-refractory immune checkpoint inhibitor associated myocarditis with tofacitinib"],"prefix":"10.3389","volume":"17","author":[{"given":"Defei","family":"Kong","sequence":"first","affiliation":[{"name":"Department of Geriatrics, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxia","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojuan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Yuan","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anli","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingmin","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Geriatrics, Shandong Provincial Hospital Affiliated to Shandong First Medical University","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"Postow","year":"2015","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B7","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","article-title":"Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer","volume":"17","author":"Cheng","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.07.020","article-title":"Deficient mismatch repair\/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment","volume":"175","author":"Taieb","year":"2022","journal-title":"Eur J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111611","article-title":"Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis","volume":"41","author":"Won","year":"2022","journal-title":"Cell Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2025.09.006","article-title":"Molecular mechanisms and therapies of immune checkpoint inhibitor associated myocarditis: Update on recent developments","volume":"116","author":"Li","year":"2025","journal-title":"Semin Cancer Biol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the european hematology association (EHA), the european society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor-associated myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1903064","article-title":"Alemtuzumab for immune-related myocarditis due to PD-1 therapy","volume":"380","author":"Esfahani","year":"2019","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.09.080","article-title":"Tocilizumab for fulminant programmed death 1 inhibitor-associated myocarditis","volume":"15","author":"Wang","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1161243","article-title":"Drug therapy for myocarditis induced by immune checkpoint inhibitors","volume":"14","author":"Wu","year":"2023","journal-title":"Front Pharmacol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.770631","article-title":"Case series of steroid-resistant immune checkpoint inhibitor associated myocarditis: A comparative analysis of corticosteroid and tofacitinib treatment","volume":"12","author":"Wang","year":"2021","journal-title":"Front Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1078155220947141","DOI":"10.1177\/1078155220947141","article-title":"Tofacitinib for treatment in immune-mediated myocarditis: The first reported cases","volume":"27","author":"Liu","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/mog2.69","article-title":"Insight into janus kinases specificity: From molecular architecture to cancer therapeutics","volume":"3","author":"Wei","year":"2024","journal-title":"MedComm \u2013 Oncology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00438-4","article-title":"Current and future status of JAK inhibitors","volume":"398","author":"McLornan","year":"2021","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13102498","article-title":"Comparative transcriptomics of immune checkpoint inhibitor myocarditis identifies guanylate binding protein 5 and 6 dysregulation","volume":"13","author":"Finke","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.944013","article-title":"Case report: Treatment for steroid-refractory immune-related myocarditis with tofacitinib","volume":"13","author":"Xing","year":"2022","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-024-06980-x","article-title":"Higher infection risk for JAK inhibitors tofacitinib and baricitinib compared to subcutaneous biological DMARDs","volume":"43","author":"Opdam","year":"2024","journal-title":"Clin Rheumatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2990","article-title":"Factors associated with disease progression after discontinuation of immune checkpoint inhibitors for immune-related toxicity in patients with advanced non\u2013small cell lung cancer","volume":"31","author":"Pecci","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2016.02.004","article-title":"The immune biology of microsatellite-unstable cancer","volume":"2","author":"Kloor","year":"2016","journal-title":"Trends Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1056\/NEJMc2202778","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ozdede","year":"2022","journal-title":"N Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2019.1657404","article-title":"An evaluation of tofacitinib for the treatment of psoriatic arthritis","volume":"20","author":"Abdulrahim","year":"2019","journal-title":"Expert Opin Pharmacother"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1778284\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:04:03Z","timestamp":1775559843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1778284\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2026.1778284"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1778284","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"article-number":"1778284"}}